Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Yusuf Önlören, Tayibe Bal, Mehmet Çaçalik, Nefise Çuvalci Öztopra, Nagehan Didem Sarı, Behice Kurtaran, Ebubekir Şenat, Alper Gündüz, Esra Zerdali, Hasan Karsen, Ayşe Batrel, Ridvan Karaali, Rahmet Güner, Tansu Yamazhan, Şükran Köse, Nurettin Erben, Nevin Inci, İltifat Köksal, Figen Sarıgül-Yıldırım, Gülsen Yörük, Sümeyra Kömür, Sibel Kayaroğlu, Şaban Esentürk, Özgür Güngör, İlknur Esen Yıldız, Dilara İnan, Şener Barut, Mustafa Namdury, Selma Tosun, Kamuran Türkü, Alper Sener, Kenan Hızel, Nurcan Baykam, Fazilet Duygu, Esrağul Akın, Güray Can, Uğur User, Hanefi Cem Günter, Ayhan Akbulut, Güven Çelebi, Mahmut Sünnetçioğlu, Oğuz Karabacak, Hayat Kumbasar Karaosmanoğlu, Fatma Sırmatel, Fehmi Tabak

*Mustafa Kemal University Faculty of Medicine, Antakya, Turkey
1Antalya Training and Research Hospital, Antalya, Turkey
2Istanbul Training and Research Hospital, İstanbul, Turkey
3Çukurova University Faculty of Medicine, Adana, Turkey
4Department of Gastroenterology, Medeniyet University Faculty of Medicine, İstanbul, Turkey
5Department of Infectious Diseases, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey
6Department of Infectious Diseases, Haseki Training and Research Hospital, İstanbul, Turkey
7Department of Infectious Diseases and Clinical Microbiology, Harran University Faculty of Medicine, Urfa, Turkey
8Department of Infectious Diseases, Kartal Training and Research Hospital, İstanbul, Turkey
9Department of Infectious Diseases and Clinical Microbiology, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
10Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey
11Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, İzmir, Turkey
12Department of Infectious Diseases, Tepecik Training and Research Hospital, İzmir, Turkey
13Department of Infectious Diseases and Clinical Microbiology, Eskişehir Osman Gazi University, Eskişehir, Turkey
14Department of Infectious Diseases and Clinical Microbiology, Duzce University Faculty of Medicine, Duzce, Turkey
15Department of Infectious Diseases and Clinical Microbiology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
16Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey
17Department of Infectious Diseases, İstanbul Training and Research Hospital, İstanbul, Turkey
18Department of Infectious Diseases and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Turkey
19Department of Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Turkey
20Department of Infectious Diseases and Clinical Microbiology, Samsun 19 Mayıs University Faculty of Medicine, Samsun, Turkey
21Department of Infectious Diseases, Samsun Training and Research Hospital, Samsun, Turkey
22Department of Infectious Diseases and Clinical Microbiology, RTE University Faculty of Medicine, Rize, Turkey
23Department of Infectious Diseases and Clinical Microbiology, Akdeniz University Faculty of Medicine, Antalya, Turkey
24Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey
25Department of Infectious Diseases and Clinical Microbiology, Gazi University Faculty of Medicine, Gaziantep, Turkey
26Department of Infectious Diseases, Bozyaka Training and Research Hospital, İzmir, Turkey
27Department of Infectious Diseases and Clinical Microbiology, Çanakkale 18 Mart University Faculty of Medicine, Çanakkale, Turkey
28Department of Infectious Diseases and Clinical Microbiology, Çanakkale Oñak University Faculty of Medicine, Çanakkale, Turkey
29Department of Infectious Diseases and Clinical Microbiology, Gebze Training and Research Hospital, Çorum, Turkey
30Department of Infectious Diseases, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
31Department of Infectious Diseases, Ankara Namık Kemal University Faculty of Medicine, Ankara, Turkey
32Department of Infectious Diseases, Bolu İzzet Baysal University Faculty of Medicine, Bolu, Turkey
33Department of Infectious Diseases, Bolu İzzet Baysal University Faculty of Medicine, Bolu, Turkey
34Department of Infectious Diseases, Gülhane Training and Research Hospital, Ankara, Turkey
35Department of Infectious Diseases, Firat University Faculty of Medicine, Elazığ, Turkey
36Department of Infectious Diseases and Clinical Microbiology, Bulent Ecevit University Faculty of Medicine, Zonguldak, Turkey
37Department of Infectious Diseases and Clinical Microbiology, Yuzuncu Yil University Faculty of Medicine, Van, Turkey
38Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Hatay, Turkey
39Department of Infectious Diseases, Ankara Numune Training and Research Hospital, İstanbul, Turkey
40Department of Infectious Diseases and Clinical Microbiology, Bolu İzzet Baysal University Faculty of Medicine, Bolu, Turkey
41Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty of Medicine, İstanbul, Turkey

Corresponding author: Fehmi Tabak, e-mail: fehmitabak@yahoo.com

Received: April 28, 2021 Accepted: January 30, 2022 Publication Date: August 1, 2022

DOI: 10.5152/tjg.2022.21271

Content of this journal is licensed under a Creative Commons Attribution (CC BY) 4.0 International License
ABSTRACT

Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C.

Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups.

Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .658, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir + ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively).

Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.

Keywords: Age, chronic hepatitis C, direct-acting antiviral agents, elderly, Turkey

INTRODUCTION

According to the World Health Organization (WHO) report, there were an estimated 71 million people (1% of the world population) who were living with chronic hepatitis C (CHC) infection, and 1.75 million new hepatitis C virus (HCV) infections occurred worldwide. Hepatitis C virus infection prevalence and secondary liver diseases are shown to be associated with advanced age. However, elderly patients were less likely to receive recommended therapies in the past because of toxicity and poor efficacy with interferon (IFN)-based therapies.

With the advances in HCV treatment with direct-acting antivirals (DAAs), HCV infection has become curable even in difficult-to-treat patient groups, which might enable the elimination of HCV infection, although there is no effective vaccine against the HCV virus. However, because elderly cases (≥60 years of age) constitute a significant portion (40%-75%) of the burden of CHC, increasing our knowledge about the efficacy and safety of DAAs in these patient groups is crucial.

The cure of HCV with DAAs in elderly patients has been shown to be associated with a decreased incidence of liver-related events and liver-related mortality which was similar to those shown in younger patients. Furthermore, observational data from different nations’ real-life cohorts revealed that DAA treatment is effective and safe for the elderly. As is known, Turkey is located in the Eastern Mediterranean Region, which has reported the highest HCV prevalence in the world, yet little is known about the efficacy and safety of DAAs in the elderly Turkish population.

The objective of this prospective, multicenter study is to evaluate whether DAA treatment is as effective and safe for elderly Turkish patients as for younger adults.

MATERIALS AND METHODS

This nationwide, multicenter prospective, non-randomized observational study conducted by the Viral Hepatitis Society and Infectious Diseases and Clinical Microbiology Specialty Society of Turkey, including 2629 CHC patients, administered a DAA regimen to patients from 37 Turkish referral centers between April 2017 and December 2019. Patients with any prior IFN-free DAA treatment and patients aged <18 years were excluded from this study. The demographical, clinical, and laboratory data were collected via a web-based reporting system.

The participants were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years). The elderly group was further divided into 3 subgroups: 65–74 years old and ≥75 years old. Efficacy and safety were compared between 2 age groups and also subgroups of the elderly group.
Patients received 1 of the 3 DAA regimens: ledipasvir (LDV) + sofosbuvir (SOF) ± ribavirin (RBV), ombitasvir (OBV) + paritaprevir/ritonavir (PTV/r) ± dasabuvir (DSV) ± RBV, and SOF + RBV. The RBV dose was initiated based on the body weight of patients. The choice of DAA regimen and all other therapeutic decisions were at the discretion of the treating physician based on current guideline recommendations and insurance coverage.

To avoid undesirable side effects and bias related to drug–drug interactions, all medications used by the patients were controlled from online drug interactions databases.

Laboratory tests including HCV RNA level, complete blood count, serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, international normalized ratio, albumin, and alpha-fetoprotein were obtained at baseline, week 4, end of the treatment, and 12 weeks of post-treatment follow-up. Hepatitis C virus genotyping was performed only at baseline. Adherence to the DAA regimen and reported adverse events were recorded at each clinical visit.

Hepatitis C virus genotype was determined by reverse transcriptase–polymerase chain reaction (RT-PCR) with genotype-specific primers, and plasma HCV RNA levels were determined by a quantitative real-time PCR-based method routinely available in each participating center.

Serious adverse events possibly related to the treatment regimen were reported to national regulatory/public health authorities.

Elderly patients were defined in accordance with the WHO definition. Patients were identified as having cirrhosis if they had a liver biopsy showing cirrhosis (Metavir F4 or Ishak 5–6) or an ultrasound report suggesting cirrhosis (e.g., blunt liver edge, irregular surface, splenomegaly, dilated portal vein, and hypertrophic left lobe) or clinical features of cirrhosis (e.g., ascites, esophageal, or gastric varices). Cirrhotic patients with a history of variceal bleeding, ascites, or hepatic encephalopathy were defined as having decompensated cirrhosis.

The primary outcome was the proportion of patients achieving a sustained virological response (SVR), which is defined as an undetectable HCV viral load 12 weeks after the completion of treatment. The secondary outcomes identified predictors of non-SVR in the elderly group, reported adverse events (AEs) including severe adverse events (SAEs) and death, and also reported the rate of RBV dose modification/discontinuation.

Effectiveness assessments other than SVR12 included early virological response (undetectable serum HCV RNA at the end of the fourth week of the treatment), virologic breakthrough (detectable HCV RNA during the treatment when previously undetectable), and relapse (detectable HCV RNA after treatment when previously undetectable at the end of treatment).

All patients who received at least 1 dose of the DAA regimen were evaluated for safety, and serious AEs were defined based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. Hepatic decompensation was considered as a liver-related event, not an SAE.

The study was approved by the Ethics Committee of Istanbul University Cerrahpaşa - Cerrahpaşa Faculty of Medicine University Medical Faculty. Before the beginning of the study, written informed content was obtained from all participants. This study was registered at clinicaltrials.gov, with registration number NCT03145844.

Statistical Analysis

Effectiveness analysis was performed with both modified evaluable population (mEP) and per-protocol (PP) populations. The mEP population included all patients who had at least 1 post-baseline measurement for the primary outcome, while the PP population included all patients who adhered to the study protocol (completed duration of treatment and had available data for primary outcome) and those who discontinued treatment due to (S)AEs but excluded those who discontinued treatment for reasons other than (S)AEs or were lost to follow-up. All patients who received at least 1 dose of the DAA regimen (evaluable population [EP] population) were evaluated for safety.

The Statistical Package for Social Sciences version 23.0 software (IBM Corp.; Armonk, NY, USA) was used for statistical analysis. Continuous variables were expressed as median and interquartile range and compared with Mann–Whitney U test or Kruskal–Wallis test, whereas categorical variables were expressed as count and percentages and compared with chi-square or Fisher’s exact test when appropriate. A logistic regression analysis was performed to determine independent risk factors associated with treatment failure in the mEP and PP populations. However, we
do not report their results here. Potential confounders for the multivariate model were selected based on literature and the significance of univariate analysis. Statistical significance was defined by a P-value of less than .05.

**Propensity Score Matching Analysis**
To reduce the effects of possible confounding factors and eliminate selection bias, a propensity score matching analysis was performed by matching ≥65 years and <65 years groups to select patients with similar baseline characteristics in mEP and PP populations. After estimation of the propensity scores based on potential confounders, ≥65 years patients were propensity score matched using a simple 1 : 1 nearest-neighbor matching without replacement to <65 years patients. We used a caliper of width equal to 0.2 of the standard deviation of the logit of the propensity score. Standardized differences were calculated to assess group balances before and after the weights with imbalance being defined as an absolute value greater than 0.20 (small effect size). R program (version 4.1.1 for Mac) was used for statistical analysis.

**RESULTS**

**Characteristics of Patients**
During the study period, 2713 patients underwent treatment with a DAA regimen. Of those, 2629 patients who fulfilled inclusion criteria were included in the study.

Our unmatched initial cohort included 2629 patients, 850 (32.3%) were ≥65 years of age, of whom 197 (23.1%) patients were ≥75 years, and 1779 (67.7%) were <65 years of age. By matching the 2 age groups for demographics and pretreatment risk factors for non-SVR, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from mEP and PP populations were included in the outcome analysis. The study flowchart is provided in Figure 1.

Table 1 presents the comparison of demographics and baseline clinical characteristics of the age groups before and after matching in mEP and PP populations. The higher proportion of comorbidity, treatment experience, cirrhosis, genotype 1 (GT1) infection, hepatocellular carcinoma (HCC), and female gender in the ≥65 years group compared to <65 years group seen in the unmatched mEP and PP populations were no longer significant after matching (Table 1).

The ≥65 years group had a significantly higher proportion of patients infected with HCV genotype 1, while infection with genotype 2 was more frequent in younger adults in the PP population (Figure 2).

The details of the 3 DAA regimens received and the usage frequency of RBV in the 2 age groups are presented in Table 2. The majority of the patients received paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD)-based regimen in the elderly group as well as in younger ones (53.9% and 70.3%, respectively). On the contrary, the rate and also the number of patients receiving LDV/SOF ± RBV combination in the <65 years group were quite low (27.7% [172/622]) as compared with the ≥65 years group (41.8% [260/622]).

**Effectiveness Analysis**
A total of 1516 (758 in each age group) and 1244 (622 in each age group) patients in the mEP and PP populations were included for treatment outcome analysis, respectively.

Both in the unmatched and matched populations, 2 age groups showed similar SVR rates (P = .938 and P = .897 for mEP, P = .577 and P = .058 for PP population, respectively) (Table 3). Likewise, patients ≥75 years of age had similar SVR rates compared to those of 65-74 years of age among the unmatched ≥65 years group (P = 1.000, 99.2% vs 98.8%, respectively, in the PP analysis and P = .06, 82.9% vs 88.1% in the mEP analysis).

Figure 3A and B shows SVR12 rates stratified by potential confounders in mEP analysis and in PP analysis, respectively. Additionally, matched age groups were compared in terms of SVR12 status according to these variables (Forrest plot in Figure 3A and B). Sustained virological response12 rates of CHC patients were similar between different DAA regimens (for OBV/PTV/r + DSV, LDV/SOF, and SOF + RBV, respectively) both in mEP analysis (87%, 87%, and 88%, respectively) and PP analysis (98%, 98%, and 92%, respectively). The SVR12 (+) group in the mEP population had a significantly higher proportion of treatment experience, while the male gender was significantly more frequent in the non-SVR group (P = .012 and P = .045, respectively) (Figure 3A).

The results of the PP analysis revealed that male gender, patients who had a prior history of HCC, patients infected with non-GT1 HCV, and patients treated with SOF + RBV had a lower SVR12 rates (P < .001, P = .047, P = .013, and P = .025, respectively) (Figure 3B).

The SVR in the CHC patients was not affected by age and the presence of cirrhosis both in the mEP and PP
Figure 1. Flowchart showing the selection of the study populations. EP, evaluable population; mEP, modified evaluable population; PP, per-protocol populations.
Table 1. Baseline Demographics and Clinical Characteristics Before and After Propensity Score Matching of the Age Groups in Modified Evaluable Population (mEP) and Per-Protocol (PP) Population

| Characteristics                      | mEP population | Before Matching | n (%) | After Matching | n (%) | P   | PP population | Before Matching | n (%) | After Matching | n (%) | P   |
|--------------------------------------|----------------|----------------|-------|----------------|-------|-----|---------------|----------------|-------|----------------|-------|-----|
| ≥65 years                            | n = 797        |                |       |                | n = 758 |    |   | n = 623        |                |       |                | n = 622 |    |   |
| ≥65 years                            | n = 1685       |                |       |                | n = 758 |    |   | n = 1395       |                |       |                | n = 622 |    |   |
| Gender, male                         | 305 (38.3)     | 929 (55.2)     | <.001 | 301 (50.4)     | 306 (50.4) | .834 | 237 (38.0)    | 758 (54.4)     | <.001 | 237 (38.1)    | 261 (42.0) | .086 |
| Cirrhosis                            | 192 (24.1)     | 190 (11.3)     | <.001 | 154 (50.2)     | 153 (49.8) | 1.000 | 157 (25.2)    | 133 (9.5)      | <.001 | 157 (25.2)    | 79 (12.7)  | <.001 |
| GT1                                  | 751 (94.3)     | 1372 (81.5)    | <.001 | 714 (50.0)     | 714 (50.0) | 1.000 | 581 (93.4)    | 1138 (81.6)    | <.001 | 581 (93.4)    | 587 (94.4) | .554 |
| HCC                                  | 9 (1.1)        | 4 (0.2)        | .004  | 2 (50.0)       | 2 (50.0)   | 1.000 | 493 (79.3)    | 589 (42.3)     | <.001 | 493 (79.3)    | 489 (78.6) | .835 |
| Treatment experience                 | 362 (45.5)     | 576 (34.2)     | <.001 | 333 (49.5)     | 340 (50.5) | .756  | 302 (48.6)    | 526 (37.7)     | <.001 | 302 (48.6)    | 332 (53.4) | .100 |
| Comorbidity                          | 402 (50.5)     | 715 (42.4)     | .093  | 384 (50.6)     | 412 (54.3) | .862  | 493 (79.3)    | 589 (42.3)     | <.001 | 493 (79.3)    | 489 (78.6) | .835 |
| Baseline HCV RNA, ≥800 000 IU/mL     | 360 (45.2)     | 765 (45.4)     | .968  | 327 (43.1)     | 345 (45.5) | .817  | 312 (50.1)    | 662 (47.5)     | .834  | 312 (50.1)    | 274 (44.0) | .089 |

Data were expressed as n (%).

GT1, genotype 1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; RNA, ribonucleic acid; mEP, modified evaluable population; PP, per-protocol population.

populations (P = .879 and P = .508 for mEP population and P = .058 and P = .788 for PP analysis, respectively) (Figure 3A and B).

**Safety Analysis**

A total of 2629 patients in the EP were included for safety analysis. Even though the elderly patients had significantly

---

Figure 2. Genotype distribution according to age groups: ≥65 years (A) versus <65 years (B).
higher rates of AEs than younger adults (20.1% vs 13.6%, $P < .001$ in EP analysis), AEs were generally mild and occurred at low rates even in patients $\geq 75$ years of age (16.8% [33/196]).

The most common AEs in the elderly group were fatigue, anemia, and pruritus (9.3%, 9.1%, and 7.9%, respectively). Fatigue and pruritus were more common in the elderly group, whereas headache was more common in the younger adults group (Table 4). AEs reported by $\geq 2\%$ of the patients for both age groups are shown in Table 4.

Severe AEs leading to treatment discontinuation were slightly more common in elderly patients than in younger adults (0.35% [3/850] vs [7/1779] 0.39%, respectively) (Table 4). Nevertheless, the frequency of discontinuation of DAAs due to SAEs was low even in patients aged $\geq 75$ years old (1% [2/196]). A complete list of serious AEs is demonstrated in Table 5.

The elderly patients had a relatively higher mortality rate than young adults (1.65% [14/850] vs 0.39% [7/1779]). Interestingly, the mortality in the elderly was mostly due to comorbidities (64.2% [9/14]) but partly due to liver-related events (21.4% [3/14]). Nevertheless, mortality rates due to liver-related events in the younger adults group were similar to those due to coexisting comorbidities (0.16% [3/1779] vs 0.22% [4/1779]).

In the elderly group, 3 patients died due to liver-related event (3 hepatic decompensation), while 2 patients died due to non-liver-related events (1 acute renal failure and 1 necrotizing fasciitis). Among the younger adults group, 3 patients died due to liver-related events (2 newly detected hepatocellular carcinomas and 1 hepatic decompensation). No SAE-related death was observed both in older and younger adults groups.

Of the 4 patients in the elderly group who died or experienced treatment discontinuation due to hepatic decompensation, 3 received PrOD regimen and 1 received LDV/SOF regimen. On the other hand, only 1 patient who received the PrOD regimen experienced hepatic decompensation in the younger adults group.

In the current study, AEs were significantly higher in patients receiving RBV-containing DAA regimens compared to those receiving DAA regimens without RBV (25.9% [41/158] vs 18.8% [129/688], respectively, $P = .042$).

The use of RBV-containing regimens was more frequent in younger adults than in elderly patients (36.6% and 18.7%, respectively). However, the rates of RBV dose reduction/discontinuation in the elderly were found to be considerably higher than that reported for younger adults ($P = .036$, 6.4% and 4.5%, respectively). Meanwhile, there

### Table 2. DAA Regimens According to Age Groups in PP population

| Characteristics | ≥ 65 years (n = 622) | <65 years (n = 622) | Total (n = 1244) |
|-----------------|---------------------|-------------------|-----------------|
| OBV/PTV/r ± DSV ± RBV | 335 (53.9) | 437 (70.3) | 772 (62.1) |
| LDV/SOF ± RBV | 260 (41.8) | 172 (27.7) | 432 (34.7) |
| SOF + RBV | 27 (4.3) | 13 (2.1) | 40 (3.2) |
| The usage frequency of RBV | 82 (13.1) | 102 (16.3) | 184 (14.7) |

Data were expressed as n (%).

DSV, dasabuvir; LDV, ledipasvir; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir, RBV, ribavirin; SOF, sofosbuvir.

### Table 3. Comparison of the SVR12 Rates Before and After Propensity Score Matching According to Age Groups in mEP and PP Populations

| Characteristics | mEP Population | PP Population |
|-----------------|----------------|--------------|
| | SVR12 (+) | Non-SVR | $P$ | SVR12 (+) | Non-SVR | $P$ |
| Before matching | | | | | | |
| ≥65 years | 692 (86.9) | 104 (13.1) | .938 | 615 (98.8) | 7 (1.2) | .577 |
| <65 years | 1465 (87.0) | 218 (13.0) | 1374 (98.5) | 20 (1.5) |
| After matching | | | | | | |
| ≥65 years | 657 (86.7) | 101 (13.3) | .879 | 615 (98.8) | 7 (1.2) | .058 |
| <65 years | 659 (86.9) | 99 (13.1) | 606 (97.4) | 16 (2.6) |

Data were expressed as n (%).
mEP, modified evaluable population; PP, per-protocol population; SVR, sustained virological response.
was no evidence that these higher rates in elderly patients had an influence on reducing their treatment responses (Table 3).

**DISCUSSION**

Magnificent progress has been made in the treatment of hepatitis C with the introduction of IFN-free DAAs with extremely high cure rates and minimal side effects in the general population. There is no reported upper age limit for DAA treatment in the current guidelines. Despite this, the elderly patients remain a group for which clinicians are hesitant to initiate DAA treatment because of negative past experiences with IFN-based treatments or economic concerns. Because it is believed that the number and proportion of elderly patients living with hepatitis C infection will increase in the coming years, increasing real-world data on the elderly Turkish population to characterize the efficacy and safety of DAA treatment is essential. This large nationwide study provides evidence that Turkish elderly CHC patients have similar high SVR rates and approximately identical safety profile to DAAs compared with younger adults.

The SVR in the elderly was not affected by the patient’s age or cirrhosis in the current study. These results are broadly consistent with earlier findings from other cohorts of different countries. However, this finding is contrary to that of Qureshi et al who found that
advancing age negatively affects the HCV treatment outcomes in the case of cirrhosis. This inconsistency may be due to Qureshi et al.'s findings that might be somewhat limited by the small sample size, particularly in the elderly (≥70 years of age) group, and the lack of information on the severity of liver diseases in most of the cases. Since it has been suggested that decompensated cirrhosis may be a risk factor for treatment failure, the low SVR rate observed in their study could be probably due to a high rate of cirrhotic subjects in Child-Turcotte-Pugh-B/C (CTP-B/C) class.23

Patients with active HCC were found to be associated with a worse response to DAA treatment compared with those without HCC.24-26 Although it is not clear why such a low SVR rate was seen in patients with active HCC, previously, it has been hypothesized that HCV within tumor cells could be relatively inaccessible to DAA agents. It is interesting to note that the present study identified a prior history of HCC as a potential predictor of treatment failure. While this result is consistent with the results

Table 4. Adverse Events by Age Groups in Evaluable Population (EP)

| Variables                        | ≥65 Years (n = 850) | <65 Years (n = 1779) | P     |
|----------------------------------|---------------------|----------------------|-------|
| Any AE, n (%)                   | 170 (20.1)          | 242 (13.6)           | <.001 |
| Grade 2 or 3 hyperbilirubinemia | 23 (2.7)            | 33 (1.9)             | .156  |
| Significant anemia (Hb <10 g/dL) | 77 (9.1)            | 79 (4.5)             | <.001 |
| RBV dose reduction or discontinuation | 54 (6.4)          | 79 (4.5)             | .036  |

Common AEs (≥2%)

| Variables                        | ≥65 Years (n = 850) | <65 Years (n = 1779) | P     |
|----------------------------------|---------------------|----------------------|-------|
| Fatigue                          | 79 (9.3)            | 117 (6.4)            | .008  |
| Pruritus                         | 67 (7.9)            | 80 (4.5)             | <.001 |
| Insomnia                         | 20 (2.4)            | 51 (2.9)             | .450  |
| Headache                         | 21 (2.5)            | 80 (4.5)             | .014  |
| Nausea                           | 32 (3.8)            | 43 (2.3)             | .051  |

Data were expressed as n (%).

AEs, adverse events; Hb, hemoglobin; RBV, ribavirin.

Table 5. Severe Adverse Events According to Age Groups in Evaluable Population (EP)

| Patient ID | Age, Years | Gender | SAE                        | Regimen          | Time After Treatment Initiation (Weeks) | Cirrhosis Status | Leading to Treatment Discontinuation |
|------------|------------|--------|----------------------------|------------------|----------------------------------------|------------------|--------------------------------------|
| ≥65 years  |            |        |                            |                  |                                        |                  |                                      |
| 1          | 71         | F      | Exacerbated dyspnea        | LDV/SOF          | 8                                      | Non-cirrhotic    | Treatment discontinuation            |
| 2          | 68         | F      | Angioedema                 | OBV/PTV/r + DSV  | 1                                      | Non-cirrhotic    | Treatment discontinuation            |
| 3          | 83         | M      | Severe constipation        | OBV/PTV/r + DSV  | 8                                      | Non-cirrhotic    | Treatment discontinuation            |
| <65 years  |            |        |                            |                  |                                        |                  |                                      |
| 1          | 57         | M      | Angioedema                 | OBV/PTV/r + DSV  | 8                                      | Non-cirrhotic    | Treatment discontinuation            |
| 2          | 61         | F      | Severe urticaria           | OBV/PTV/r + DSV  | 4                                      | CTP-A            | Treatment discontinuation            |
| 3          | 45         | M      | Severe bleeding            | SOF + RBV        | 5                                      | Non-cirrhotic    | Treatment discontinuation            |
| 4          | 57         | F      | Severe constipation        | OBV/PTV/r + DSV  | 4                                      | Non-cirrhotic    | Treatment discontinuation            |
| 5          | 62         | F      | Severe constipation        | OBV/PTV/r + DSV  | 2                                      | Non-cirrhotic    | Treatment discontinuation            |
| 6          | 52         | F      | Severe constipation        | OBV/PTV/r + DSV  | 5                                      | Non-cirrhotic    | Treatment discontinuation            |
| 7          | 57         | F      | Exacerbation of psychosis  | LDV/SOF          | 6                                      | CTP-A            | Treatment discontinuation            |

Data were expressed as n (%).

SAE, severe adverse event; DSV, dasabuvir; LDV, ledipasvir; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; CTP, Child–Turcotte–Pugh.
of some researchers, others have failed to find a link between a prior HCC history and non-SVR. Because it is well known that prior HCC is associated with increased risk of de novo HCC, we hypothesized that the presence of a possible baseline HCC could not be seen radiologically (maybe in the early stage) in patients with prior HCC might negatively affect SVR. Hence, caution must be applied when comparing this finding with previously reported studies. Furthermore, well-designed matched control studies with long-term follow-up are warranted to confirm this finding.

Additionally, the male gender was found to be associated with treatment failure in the current study. Since this result has not been found elsewhere, it is difficult to explain this result, but it is probably due to the fact that older men with a long history of HCV infection are more likely to have advanced cirrhosis/liver disease than older women, which can decrease cure rates.

In the current study, subgroup analysis stratified by different DAA regimens and potential confounders in non-SVR yielded excellent SVR rates, while SOF + RBV had lower SVR rates than other regimens in the PP population (>97% and 92%, respectively). However, it may not be appropriate to make a definitive conclusion since patients in the 3 treatment arms were not homogeneous. The results of our study are partly in line with the general medical literature, in which SOF + RBV combination treatment is known to have generally low rates of SVR, and this combination is no longer a preferred regimen by The American Association For The Study of Liver Diseases (AASLD). Thus, it was surprising that we observed excellent SVR rates (92%) with SOF + RBV treatment in the PP population, even though the deficient number of patients (n = 40, 3.2% of the population) in this treatment arm prevented a clear conclusion from this finding. In reviewing the literature, the response rate for this regimen in the elderly is low in Western countries (88.2%) but is higher (97%) in Asian countries. These differences in SVR rates have been attributed to the lower body mass index and predominance of CC IL28B alleles in the Asian population/Asians. As a result, racial differences could help to explain the high response rates with SOF + RBV observed in the present study, which is supported by a recent study from Turkey.

Direct-acting antivirals were generally well tolerated in the current study, even in patients aged 75 years and older. Additionally, the most common AEs in the elderly were fatigue, anemia, and pruritus in the present study, which corresponded to those previously reported in elderly populations from different countries. Surprisingly, the prevalence of AEs in our elderly group was 21%, relatively lower than the rates reported in previous studies which range from 24% up to 95%. This lower percentage of AEs in the present study may reflect differences in study protocols, treatment populations, or covariate adjustment, and it will require further studies. However, not surprisingly, we found that the frequency of AEs was higher when DAA regimens were combined with RBV compared with DAAs alone, which is supported by previous reports. Although the use of RBV-containing regimens was more frequent in younger adults than in elderly patients (36.6% and 18.7%, respectively), the incidences of RBV dose reduction/discontinuation in the elderly were found to be considerably higher than those in younger adults. However, this did not adversely affect the SVR, which is consistent with earlier observations. Based on these findings, the use of RBV should be avoided in elderly patients because of the increased risk of AEs such as anemia. Similar to the results of Dultz et al., we found that headache was more common among younger adults than elderly patients. However, according to another study, similar rates of headache in elderly patients in comparison to their younger counterparts were found. These higher rates of headache in younger adults could be attributed to higher rates of the use of RBV-containing regimens in younger adults than elderly patients in the current study. Indeed, in a study by Bräu et al., they attributed headaches to RBV-based regimens.

In the present study, although the incidence of serious AEs increased with age, premature discontinuation of DAAs or death due to SAEs was uncommon (less than 1%) even in those ≥75 years of age. These results are similar to those obtained by Dultz et al., while the incidences observed in the current study are far below those observed by Lens et al., who have suggested that advanced age (≥75 years of age) and liver cirrhosis are associated with an increased incidence of SAEs-related premature discontinuation. Consequently, it is possible that our results may have been influenced by the low proportion of patients with advanced age and cirrhosis in the present study.

Another point worth mentioning is that in the current study, we accepted newly diagnosed hepatic decompensation as a liver-related event, not as an SAE. Even though hepatic decompensation during DAA treatment...
is classified and reported as an SAE in the vast majority of previous studies, recent findings from several studies suggest that this liver-related event might be due to the natural course of advanced cirrhosis rather than being directly related to DAA treatment.\textsuperscript{41-43} This view is also supported by the fact that elderly patients with CHC cases are at a high risk of developing end-stage liver disease even after eradication of HCV, because the regeneration of the liver is slow and usually incomplete following a liver injury.\textsuperscript{44,45} Recently, a meta-analysis including more than 3400 patients (70\% of these had cirrhosis) reported that the rates of hepatic decompensation in patients undergoing treatment with a DAA regimen are lower than the estimated rates of annual hepatic decompensation in patients with compensated cirrhosis (0.96\% vs 5\%-7\%) that never received DAA treatment.\textsuperscript{46} Thus, there are still unanswered questions about the safety of DAAAs, especially in patients with cirrhosis, upon which future investigations should focus.

Elderly patients had a higher all-cause mortality rate compared with younger patients. This high rate could, however, mainly be attributed to non-liver-related comorbidities. These results are consistent with those of other studies and support the idea that DAA treatment reduces liver-related events and related mortality in elderly as well as in younger adults.\textsuperscript{8,40}

The major limitation of this study was that non-homogeneous distributions exist among treatment agents, which limited our ability to compare the efficacy and safety of different DAA regimens. On the other hand, the prospective nature and multicenter setting were the major strengths of our study.

The results of the current study suggested that DAA regimens can be safely used to treat Turkish elderly CHC patients with similar favorable efficacy as that in younger adults, even for those aged 75 years and over. Elderly patients with a prior history of HCC and of the male gender, however, are at higher risk for treatment failure. Nevertheless, future research is needed to address the causal nature of these relations.

**Ethics Committee Approval:** Ethical committee approval was received from the Ethics Committee of Istanbul University-Cerrahpasa University (Date: 07 March 2017; Approval No: 59491012-604.01.02).

**Informed Consent:** Written informed consent was obtained from the participants who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept – F.T., Y.Ö.; Design – F.T.; Data Collection and/or Processing – Y.Ö., T.B., M.C., NÇ.O., N.D.S., B.K., E.S., A.G., E.Z., H.K., A.B., R.K.A., R.G., T.Y., S.K., N.E., N.I., İ.N., İ.K., F.S.Y., G.Y., S.K., S.K., Ş.E., Ö.G., İ.E.Y., D.I., Ş.B., M.N., S.T., K.T., A.S., K.H., N.B., F.D., E.A., G.C., Ü.U., H.C.G., A.A., G.C., M.S., O.K., H.K.K., F.S., F.T. and Hep-C Turkey Study Group; Analysis and/or Interpretation – Y.Ö.; Literature Search – Y.Ö.; Writing Manuscript – Y.Ö.

**Declaration of Interests:** The authors have no conflict of interest to declare.

**Funding:** This study received no funding.

**REFERENCES**

1. World Health Organization. WHO model list of essential medicines. Available at: https://www.who.int/medicines/publications/essential medicines/en/. Accessed December 12, 2019.

2. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32(1):111-115. [CrossRef]

3. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol. 2017;29(6):686-693. [CrossRef]

4. Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci. 2008;53(3):809-814. [CrossRef]

5. Mücke MM, Herrmann E, Mücke VT, Graf C, Zeuzem S, Vermehren J. Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: a systematic review and meta-analysis. Liver Int. 2019;39(9):1652-1660. [CrossRef]

6. Yang Z, Zhuang L, Yang L, et al. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥65 years with chronic hepatitis C: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38(4):404-460. [CrossRef]

7. Kinchen VJ, Cox AL, Bailey JR. Can broadly neutralizing monoclonal antibodies lead to a hepatitis C virus vaccine? Trends Microbiol. 2018;26(10):854-864. [CrossRef]

8. Jhaveri MA, Manne V, Kowdle KW. Chronic hepatitis C in elderly patients: current evidence with direct-acting antivirals. Drugs Aging. 2018;35(2):117-122. [CrossRef]

9. Rodríguez-Osorio I, Mena A, Mejide H, et al. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One. 2019;14(6):e0217052. [CrossRef]

10. Patel A, Backstedt DW, Abidali H, Choi M, Pedersen M, Seetharam A. Effectiveness and tolerability of direct acting antiviral therapy for hepatitis C in a real world elderly cohort. Clin Gastroenterol Hepatol. 2017;15(4):803-804. [CrossRef]

11. Villari R, Donatiello I, Barone F, et al. Efficacy and safety of direct-acting antivirals in elderly with hepatitis C: results from a retrospective cohort study. J Gerontol Geriatr. 2018;66:46-55.

12. Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct-acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856-865. [CrossRef]
13. Tözün N, Ozdoğan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026. [CrossRef]

14. Cabalak M, Bal T. Effectiveness of oral direct acting antivirals in elderly chronic hepatitis C patients: real world data. Turk Geriatr Derg.23(4):473-481. [CrossRef]

15. World Health Organization (WHO). Definition of an older or elderly person from 2012. Available at: http://www.who.int/healthinfo/survey/yageingdefholder/en/. Accessed February 18, 2013 [Ref list].

16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1999;24(2):289-293. [CrossRef]

17. Available at: https://step.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed December 09, 2019.

18. American Association for the Study of Liver Disease Practice guidelines. Available at: https://www.aasld.org/publications/practice-guidelines. Accessed December 27, 2019.

19. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21, 521e1, 521.e1-521.e6. [CrossRef]

20. Pan CQ, Gayam V, Rabinovich C, et al. Efficacy of direct-acting antivirals for chronic hepatitis C in a large cohort of older adults in the United States. J Am Geriatr Soc. 2020;68(2):379-387. [CrossRef]

21. Dultz G, Müller T, Petersen J, et al. Effectiveness and safety of direct-acting antiviral combination therapies for treatment of hepatitis C virus in elderly patients: results from the German hepatitis C registry. Drugs Aging. 2018;35(9):843-857. [CrossRef]

22. Qureshi K, Petersen T, Andres J. Hepatitis C treatment differences in elderly patients: single-center retrospective study. Ann Pharmacother. 2020;54(2):113-121. [CrossRef]

23. Conti F, Brillanti S, Buonfiglioli F, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24(6):454-463. [CrossRef]

24. Prenger SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173-1181. [CrossRef]

25. Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatol. 2019;71(3):473-485. [CrossRef]

26. Yen YH, Chen CH, Hung CH, et al. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data. PLoS One. 2019;14(10):e0222605. [CrossRef]

27. Sugiuara A, Joshita S, Umemura T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat. 2018;25(12):1462-1471. [CrossRef]

28. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727-733. [CrossRef]

29. EASL Recommendations on treatment of hepatitis C 2018. European Association for the study of the liver. J Hepatol. 2018;69(2):461-511. [CrossRef]

30. American Association for the Study of Liver Diseases. IDSA HCV guidance panel. hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477-1492. [CrossRef]

31. Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66(10):1844-1852. [CrossRef]

32. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762-768. [CrossRef]

33. Kao JH, Ahn SH, Chien RN, et al. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol. 2017;32(5):966-974. [CrossRef]

34. Bal T, Cabalak M. Sofosbuvir and ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res. 2020;27(8):2067. [CrossRef]

35. Medeiros T, Salvatmo CM, do Rosário NF, et al. Adverse effects of direct-acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm. 2019;37(6):1304-1311. [CrossRef]

36. Reid M, Price JC, Tien PC. Hepatitis C virus infection in the elderly patient. Infect Dis Clin North Am. 2017;31(4):827-838. [CrossRef]

37. Dultz G, Müller T, Petersen J, et al. Leberstiftungs-GmbH Deutschland. Drugs Aging. 2018;36(9):843-857. [CrossRef]

38. Shergar JM, Gayam V, Khan A, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2017;29(7):767-776. [CrossRef]

39. Brau N, Bini EJ, Stancic S, Finch DA, Aytaman A. Severe migraine headaches are caused by ribavirin but not by interferon alpha-2b in combination therapy for chronic hepatitis C. J Hepatol. 2003;38(6):871-872. [CrossRef]

40. Lens S, Fernández I, Rodríguez-Tajes S, et al. Interferon-free therapy in elderly patients with advanced liver disease. Am J Gastroenterol. 2017;112(9):1400-1409. [CrossRef]

41. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):849-859. [CrossRef]

42. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64(4):790-799. [CrossRef]

43. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64(4):763-765. [CrossRef]

44. Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother. 2017;18(17):1867-1874. [CrossRef]

45. Collins BH, Holzknecht ZE, Lynn KA, et al. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013;33(8):1175-1186. [CrossRef]

46. Wedemeyer H, Crazi A, Zuckerman E, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24(11):936-943. [CrossRef]